Business combinations (Tables)

9 Months Ended

Sep. 30, 2020

Summary of purchase price and post-combination expense

The following table summarizes the purchase prices recorded as a part of the acquisition of Genelex and YouScript (in thousands):



	Genelex		YouScript		Total
Cash transferred	$	972	$	24,462	$	25,434
Hold-back consideration - cash	—		1,385		1,385
Hold-back consideration - common stock	781		5,392		6,173
Contingent consideration	1,994		—		1,994
Common stock transferred	9,463		21,464		30,927
Total	$	13,210	$	52,703	$	65,913

The following table summarizes the purchase price recorded as a part of the acquisition of Diploid (in thousands):



	Purchase Price
Cash transferred	$	32,323
Hold-back consideration - common stock	7,538
Common stock transferred	42,453
Total	$	82,314

Summary of fair values of assets acquired and liabilities assumed

The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisitions of Genelex and YouScript at the date of acquisition (in thousands):



	Genelex			YouScript			Total
Cash	$	33		$	24		$	57
Accounts receivable	221			56			277
Prepaid expenses and other current assets	—			70			70
Operating lease assets	—			355			355
Developed technology	9,209			25,716			34,925
Total identifiable assets acquired	9,463			26,221			35,684
Current liabilities	(320		)	(481		)	(801		)
Deferred tax liability	—			(2,600		)	(2,600		)
Other long-term liabilities	—			(163		)	(163		)
Net identifiable assets acquired	9,143			22,977			32,120
Goodwill	4,067			29,726			33,793
Total purchase price	$	13,210		$	52,703		$	65,913

The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisition of Diploid at the date of acquisition (in thousands):



Cash	$	124
Accounts receivable	26
Developed technology	41,789
Total identifiable assets acquired	41,939
Accounts payable	(30		)
Deferred tax liability	(10,250		)
Net identifiable assets acquired	31,659
Goodwill	50,655
Total purchase price	$	82,314